Publication: Vaginal misoprostol for cervical priming before dilatation and curettage in postmenopausal women: A randomized controlled trial
2
Issued Date
2004-06-01
Resource Type
ISSN
13418076
Other identifier(s)
2-s2.0-3042829485
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Obstetrics and Gynaecology Research. Vol.30, No.3 (2004), 221-225
Suggested Citation
Soysuwan Bunnasathiansri, Yongyoth Herabutya, Pratak O-Prasertsawat Vaginal misoprostol for cervical priming before dilatation and curettage in postmenopausal women: A randomized controlled trial. Journal of Obstetrics and Gynaecology Research. Vol.30, No.3 (2004), 221-225. doi:10.1111/j.1447-0756.2004.00190.x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/21632
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Vaginal misoprostol for cervical priming before dilatation and curettage in postmenopausal women: A randomized controlled trial
Other Contributor(s)
Abstract
Aim: To investigate the efficacy of vaginal misoprostol for cervical priming before dilatation and curettage in postmenopausal women. Methods: Forty-four postmenopausal women with indication for dilatation and curettage were randomly assigned to receive either 400 μg of misoprostol or placebo vaginally 6 h before dilatation and curettage. The main outcome measures were the number of women who required cervical dilatation, cervical width, time taken to dilate to Hegar 6 and other complications. Results: The mean cervical diameter (4.59 millimeters in the misoprostol group vs 4.41 millimeters in the placebo group) was comparable between the two groups. A similar number of women in the misoprostol group and in the placebo group required cervical dilatation (12 vs 16, P = 0.35). The operative times for both groups were similar. The incidence of side-effects was comparable in both groups. There were two uterine perforations in the misoprostol group (2 vs 0). Conclusion: There was no significant benefit from applying 400 μg vaginal misoprostol 6 h prior to dilatation and curettage in postmenopausal women.